Economic evaluation of three populational screening strategies for cervical cancer in the county of Valles Occidental: CRICERVA clinical trial
- PMID: 22011387
- PMCID: PMC3215283
- DOI: 10.1186/1472-6963-11-278
Economic evaluation of three populational screening strategies for cervical cancer in the county of Valles Occidental: CRICERVA clinical trial
Abstract
Background: A high percentage of cervical cancer cases have not undergone cytological tests within 10 years prior to diagnosis. Different population interventions could improve coverage in the public system, although costs will also increase. The aim of this study was to compare the effectiveness and the costs of three types of population interventions to increase the number of female participants in the screening programmes for cancer of the cervix carried out by Primary Care in four basic health care areas.
Methods/design: A cost-effectiveness analysis will be performed from the perspective of public health system including women from 30 to 70 years of age (n = 20,994) with incorrect screening criteria from four basic health care areas in the Valles Occidental, Barcelona, Spain. The patients will be randomly distributed into the control group and the three intervention groups (IG1: invitation letter to participate in the screening; IG2: invitation letter and informative leaflet; IG3: invitation letter, informative leaflet and a phone call reminder) and followed for three years. Clinical effectiveness will be measured by the number of HPV, epithelial lesions and cancer of cervix cases detected. The number of deaths avoided will be secondary measures of effectiveness. The temporal horizon of the analysis will be the life expectancy of the female population in the study. Costs and effectiveness will be discounted at 3%. In addition, univariate and multivariate sensitivity analysis will be carried out.
Discussion: IG3 is expected to be more cost-effective intervention than IG1 and IG2, with greater detection of HPV infections, epithelial lesions and cancer than other strategies, albeit at a greater cost.
Trial registration: Clinical Trials.gov Identifier NCT01373723.
Figures
Similar articles
-
Analysis of three strategies to increase screening coverage for cervical cancer in the general population of women aged 60 to 70 years: the CRICERVA study.BMC Womens Health. 2014 Jul 16;14:86. doi: 10.1186/1472-6874-14-86. BMC Womens Health. 2014. PMID: 25026889 Free PMC article. Clinical Trial.
-
Increasing Cervical Cancer Screening Coverage: A Randomised, Community-Based Clinical Trial.PLoS One. 2017 Jan 24;12(1):e0170371. doi: 10.1371/journal.pone.0170371. eCollection 2017. PLoS One. 2017. PMID: 28118410 Free PMC article. Clinical Trial.
-
Cost-effectiveness of strategies to increase screening coverage for cervical cancer in Spain: the CRIVERVA study.BMC Public Health. 2017 Feb 14;17(1):194. doi: 10.1186/s12889-017-4115-0. BMC Public Health. 2017. PMID: 28196467 Free PMC article. Clinical Trial.
-
Factors Influencing the Cost-Effectiveness Outcomes of HPV Vaccination and Screening Interventions in Low-to-Middle-Income Countries (LMICs): A Systematic Review.Appl Health Econ Health Policy. 2020 Oct;18(5):641-654. doi: 10.1007/s40258-020-00576-7. Appl Health Econ Health Policy. 2020. PMID: 32468410
-
A systematic review of the cost-effectiveness of interventions to increase cervical cancer screening among underserved women in Europe.Eur J Health Econ. 2024 Jul;25(5):829-844. doi: 10.1007/s10198-023-01627-1. Epub 2023 Sep 20. Eur J Health Econ. 2024. PMID: 37726429 Free PMC article.
Cited by
-
Analysis of three strategies to increase screening coverage for cervical cancer in the general population of women aged 60 to 70 years: the CRICERVA study.BMC Womens Health. 2014 Jul 16;14:86. doi: 10.1186/1472-6874-14-86. BMC Womens Health. 2014. PMID: 25026889 Free PMC article. Clinical Trial.
-
Research can be integrated into public health policy-making: global lessons for and from Spanish economic evaluations.Health Res Policy Syst. 2022 Jun 18;20(1):67. doi: 10.1186/s12961-022-00875-6. Health Res Policy Syst. 2022. PMID: 35717247 Free PMC article.
-
Increasing Cervical Cancer Screening Coverage: A Randomised, Community-Based Clinical Trial.PLoS One. 2017 Jan 24;12(1):e0170371. doi: 10.1371/journal.pone.0170371. eCollection 2017. PLoS One. 2017. PMID: 28118410 Free PMC article. Clinical Trial.
-
Protecting the underscreened women in developed countries: the value of HPV test.BMC Cancer. 2014 Aug 8;14:574. doi: 10.1186/1471-2407-14-574. BMC Cancer. 2014. PMID: 25102758 Free PMC article.
-
Underscreened Women Remain Overrepresented in the Pool of Cervical Cancer Cases in Spain: A Need to Rethink the Screening Interventions.Biomed Res Int. 2015;2015:605375. doi: 10.1155/2015/605375. Epub 2015 Jun 9. Biomed Res Int. 2015. PMID: 26180804 Free PMC article.
References
-
- Maxwell D, Bray F. Magnitud de los cánceres atribuibles al VPH. Vaccine de. 2006;24(Sup 3):11–24.
-
- Bosch FX, Castellsagué X, Cortés J, Puig-Tintoré LM, Roura E, de Sanjose S, Torné A. Estudio AFRODITA: cribado del cáncer de cuello uterino en España y factores relacionados. Madrid: Edición patrocinada por GSK; 2009.
-
- Muñoz N, Castellsagué X, de González AB, Gissmann L. HPV in the etiology of human cancer. Vaccine de. 2006;24(Sup 3):1–10. - PubMed
-
- Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Clin Pathol. 1999;189(1):12–9. - PubMed
-
- Cortés J, Alba A, Andía D, Ramón y Cajal JM, Velasco J, Vilaplana E. Actas del Primer Foro Español sobre el Virus del Papiloma Humano: 13-14 de junio de 2008. Sevilla. Madrid: Sanofi Pasteur MSD; 2010. Interacción vacuna frente al VPH/cribado del Cáncer de Cuello de Útero.